Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities. Despite an increasing collective effort to improve health inequalities, a multitude of disparities continue to affect cardiovascular outcomes. Am...
Main Authors: | Apurva Khedagi, Cara Hoke, Michelle Kelsey, Andrea Coviello, W. Schuyler Jones, Larry R. Jackson, II, Manesh R Patel, Rob W. McGarrah, Neha J Pagidipati, Nishant P. Shah |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-03-01
|
Series: | American Journal of Preventive Cardiology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667723000193 |
Similar Items
-
SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
by: Zheer Kejlberg Al-Mashhadi, et al.
Published: (2022-08-01) -
Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01) -
SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01) -
Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
by: Dion R. P. Muller, et al.
Published: (2023-10-01) -
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
by: Bartosz Rolek, et al.
Published: (2023-07-01)